Methods and reagents for the enhancement of virus transduction in the bladder epithelium
AssigneeCell Genesys, Inc.
InventorsNagarajan Ramesh, David Frey, Bahram Memarzadeh, DeChao Yu
Life of this patent
Estimating the term…
Abstract
Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.
Claims95
A method for treating cancer of the bladder comprising:
- contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent;
- and
- subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;
- wherein the transduction enhancing agent is a mono-, di-, or poly-saccharide having a lipophilic substituent.
A method for treating cancer of the bladder comprising:
- contacting the luminal surface of the bladder with a pretreatment composition comprising about 0.01 to about 0.2% by weight sodium oxychlorosene;
- and
- subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus.
A method of treating cancer of the bladder comprising:
- contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the chemical formula:
- 30
- wherein x and y are positive integers;
- and
- subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus.
A method of treating cancer of the bladder comprising:
- contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the following general formula (I) or the following general formula (II):
- 31
- wherein x is a positive integer;
- and
- subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus.
A composition comprising:
- a transduction enhancing agent;
- and
- an oncolytic virus;
- wherein the transduction enhancing agent is a mono-, di-, or poly-saccharide having a lipophilic substituent.
A composition comprising sodium oxychlorosene and an oncolytic virus.
A method for treating cancer of the bladder comprising:
- contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent;
- and
- subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;
- wherein the transduction enhancing agent has the following general formula (I) or the following general formula (II):
- 34
- wherein X is a sulfur or oxygen atom, each R2 is independently hydrogen or a moiety represented by:
- 35
- and R1 represents an alkyl or alkenyl group;
- and
- wherein the luminal surface of the bladder is contacted with the pretreatment composition for at least 10 minutes.
A method of treating cancer of the bladder comprising:
- contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the following general formula (I) or the following general formula (II):
- 40
- wherein x is a positive integer;
- and
- subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;
- wherein x is at least 11;
- and
- wherein the oncolytic virus composition comprises at least 4×1010 viral particles.
A composition comprising:
- a transduction enhancing agent;
- and
- an oncolytic virus;
- wherein the transduction enhancing agent has a structure represented by the following general formula (I) or the following general formula (II):
- 41
- wherein x is a positive integer;
- and
- wherein the concentration of the transduction enhancing agent is less than 0.025 wt/% of the composition.
Dependencies are inferred from the claim text.